Source comparison
PT-141 vs PDE5 Inhibitors: Different Mechanisms, Different Use Cases
Primary Target MC3R/MC4R melanocortin receptors in hypothalamus PDE5 enzyme in penile smooth muscle PT-141 acts centrally; PDE5 inhibitors act peripherally Onset of Action 45–90 minutes (subcutaneous injection) 30–60 minutes (oral tablet) 60–120 minutes (oral
This comparison does not assign a generated winner or score.
- Primary Target
- MC3R/MC4R melanocortin receptors in hypothalamus
- PDE5 enzyme in penile smooth muscle
- PT-141 acts centrally; PDE5 inhibitors act peripherally
- Onset of Action
- 45–90 minutes (subcutaneous injection)
- 30–60 minutes (oral tablet)
- 60–120 minutes (oral tablet)
- PT-141 requires planning but doesn't depend on sexual stimulation
- Duration of Effect
- 4–6 hours (desire window)
- 4–5 hours (erectile support window)
- 24–36 hours (erectile support window)
- Tadalafil offers longest duration; PT-141 offers most targeted desire effect
- Primary Indication
- Hypoactive sexual desire disorder (HSDD)
- Erectile dysfunction
- Use PT-141 when desire is the issue; use PDE5 inhibitors when erection is the issue
- Effect on Libido
- Direct increase in sexual motivation and desire
- Indirect (confidence from reliable erections)
- Only PT-141 directly restores desire at the neurological level
- Side Effect Profile
- Nausea (20–35%), flushing (15–20%), hyperpigmentation (rare)
- Headache (16%), flushing (10%), nasal congestion (4%)
- Headache (11%), dyspepsia (7%), back pain (3%)
- PT-141 has higher nausea incidence but no cardiovascular contraindications
- The bottom line: if a man can achieve an erection but has no interest in initiating sex, PDE5 inhibitors won't help. They require sexual arousal to work. PT-141 generates that arousal signal centrally, making it the appropriate choice for HSDD rather than erectile dysfunction.